![Sofia Heigis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 25 553 $ al 30/06/2026
Sofia Heigis currently works at Oncopeptides AB, as Chief Executive Officer from 2023.
Ms. Heigis also formerly worked at AstraZeneca R & D Lund, as Head-Medical & Regulatory Affairs from 2018 to 2020.
Ms. Heigis received her graduate degree from Bond University and undergraduate degree from the University of Gothenburg.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ONCOPEPTIDES AB 0,04 % | 26/08/2025 | 152.475 ( 0,04 % ) | 25 553 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ONCOPEPTIDES AB | Director Ejecutivo | 07/08/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
AstraZeneca R & D Lund | Director Técnico/Científico/I+D | 01/08/2020 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Oncopeptides AB
 Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
Bond University
 Bond University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Gothenburg
 University of Gothenburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca R & D Lund |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
